Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Arpita Dutt headshot

4 Drug Stocks that are Broker Favorites

Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.

    The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines

    The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines

      Arpita Dutt headshot

      Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data

      Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.

        The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

        The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

          Arpita Dutt headshot

          4 FDA Decisions to Watch Out for in Feb 2017

          So far this year, the FDA has approved one drug. Will the pace of drug approvals pick up in February?

            Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid

            Celgene Corporation (CELG) announced that the EMA's CHMP has rendered a positive opinion for oncology drug Revlimid as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma.

              Celgene (CELG) Misses on Earnings & Revenues, Keeps View

              Celgene (CELG) reported fourth-quarter 2016 earnings of $1.41 per share (including share-based compensation expense and tax adjustments), missing the Zacks Consensus Estimate of $1.43.

                Ekta Bagri headshot

                Celgene (CELG) Misses On Q4 Earnings & Revenues

                Celgene Corporation (CELG) missed on both earnings and revenues in Q4.

                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                    Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

                    How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review

                      There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.

                        Prima Biomed Initiates Randomized Study for Breast Cancer

                        Prima (PBMD) dosed the first patient in the enlarged randomized phase of the phase IIb study -- AIPAC -- on IMP321 for the treatment of metastatic breast cancer.

                          Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

                          Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

                            4 Top Biotech Mutual Funds for 2017

                            Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

                              Medidata Solutions Clinical Cloud Gets Picked by Celgene

                              Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

                                Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

                                  Celgene Issues Preliminary 2016 Results, Lifts 2017 View

                                  Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.

                                    Halozyme (HALO) Up on Positive Phase II Data on PEGPH20

                                    Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.

                                      Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

                                      Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

                                        Prima (PBMD) Reports Favorable Initial Melanoma Study Data

                                        Prima (PBMD) announced interim data from the TACTI-mel program on IMP321 for the treatment of patients with unresectable or metastatic melanoma.

                                          The Zacks Analyst Blog Highlights: Celgene, 21st Century Fox, Prudential, Amazon and Exelon

                                          The Zacks Analyst Blog Highlights: Celgene, 21st Century Fox, Prudential, Amazon and Exelon

                                            The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

                                            The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold

                                              Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.

                                                Mark Vickery headshot

                                                Top Research Reports for December 28, 2016

                                                Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), 21st Century Fox (FOXA) and Prudential (PRU).

                                                  Arpita Dutt headshot

                                                  Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead

                                                  We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.